The concept of bioactive glass (bioglass) was developed and examined for the first time by Hench at the beginning of the 70s (
1,
2). Bioactive glass is a bone substitute material that is thought not only to have osteoconductivity, but is also responsible for osteoproduction by stimulating proliferation and differentiation of osteoprogenitor cells through a direct genetic control (
1,
3-
5). The discovery of this new material led Hench and Wilson to propose the concept of “osteostimulation” or “osteopromotion” to define this class of bioactive material and its effect on the genetic activation of bone cells (
6). Bioactive glass is a surface reactive material that, when in contact with physiological fluids, releases soluble ionic products and induces insulin-like growth factor II mRNA expression and protein synthesis that have been suggested to stimulate
in-vitro osteogenesis (
4,
7). In addition
in-vivo studies have demonstrated beneficial results from their use in various clinical situations (
8-
11). They are now clinically approved foruse in dense form in non-load bearing applications such as middle ear prosthesis and endosseous ridge implants and as a particulate for periodontal defect repair (
12-
13).They have potentials as bone replacement graft materials and have effectiveness as an adjunct to intrabony defects surgical treatment (
12-
14). Recent investigations have suggested that bioactive glasses have a much better performance in bone tissue engineering than hydroxyapatite (HA) (
4,
15-
17). After implantation, interaction with surrounding tissues results in a time-dependent alteration of the materials’ surface and the formation of a hydroxyl carbonate apatite layer that is very similar to the mineral phase of bone (
2). Results of
in-vivo implantation show that these compositions produce no local or systemic toxicity, no inflammation and no foreign-body response and possess antimicrobial properties (
18,
19).
It seems that nanostructure bioceramic has better bioactivity compared to coarser crystals (
20,
21). By controlling the structure and particle size in the range of nanoscale, some properties of bioactive glass such as osteoconductivity, sintering characters, solubility and mechanical reliability can be improved (
22). The biocompatibility and cytotoxicity of the novel biomaterials is a key issue that should be addressed prior to pre-clinical applications. Thus, the aim of this study was to evaluate and compare the cytotoxicity of a nanopowder bioactive glass with a micropowder bioactive glass named NovaBone
® as trade mark. The null hypothesis was that nanopowder bioactive glass will show an acceptable biocompatibility when compared to micropowder bioactive glass.